M Dreyling

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi request reprint Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European
    Martin Dreyling
    Department of Internal Medicine III, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Blood 105:2677-84. 2005
  2. pmc A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large ce
    Mathias Witzens-Harig
    Department of Internal Medicine V, University of Heidelberg, INF 410, 69120, Heidelberg, Germany
    BMC Cancer 13:308. 2013
  3. doi request reprint ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
    M Dreyling
    Department of Medicine III, University Hospital, LMU Munich, Germany
    Ann Oncol 24:857-77. 2013
  4. doi request reprint Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network
    Martin Dreyling
    Department of Medicine III, University Hospital Großhadern LMU Munich, Germany
    Leuk Lymphoma 54:699-707. 2013
  5. doi request reprint Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network
    Martin Dreyling
    Department of Medicine III, University Hospital Grosshadern LMU Munich, Munich, Germany
    Leuk Lymphoma 52:2226-36. 2011
  6. ncbi request reprint Hyper-CVAD in mantle-cell lymphoma: really "hyper" or just hype?
    Martin Dreyling
    Department of Medicine III, University of Munich Campus, Grosshadern, Germany
    Leuk Lymphoma 49:1017-8. 2008
  7. ncbi request reprint [Up-to-date treatment of follicular lymphomas]
    M Dreyling
    Medizinische Klinik III, Klinikum der Ludwig Maximilians Universität München, Grosshadern
    Dtsch Med Wochenschr 130:2149-54. 2005
  8. doi request reprint Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
    Martin Dreyling
    University Hospital Grosshadern, Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
    Curr Opin Oncol 20:487-94. 2008
  9. ncbi request reprint Combination of biologicals in indolent lymphoma: finally the end of chemotherapy era in indolent lymphoma?
    Martin Dreyling
    Medizinische Klinik III der Universität Münich Grosshadern, Germany
    Leuk Lymphoma 49:8-9. 2008
  10. ncbi request reprint [Therapy of mantle cell lymphoma]
    M Dreyling
    Med Klinik und Poliklinik III, Klinikum der Universitat Munchen Grosshadern, Marchioninistrasse 15, 81377, Munchen, Deutschland
    Internist (Berl) 48:382-8. 2007

Collaborators

Detail Information

Publications71

  1. ncbi request reprint Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European
    Martin Dreyling
    Department of Internal Medicine III, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Blood 105:2677-84. 2005
    ..18). Early consolidation by myeloablative radiochemotherapy followed by ASCT is feasible and results in a significant prolongation of PFS in advanced-stage MCL. Longer follow-up is needed to determine the effect on OS...
  2. pmc A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large ce
    Mathias Witzens-Harig
    Department of Internal Medicine V, University of Heidelberg, INF 410, 69120, Heidelberg, Germany
    BMC Cancer 13:308. 2013
    ..Therefore there is an ultimate need for improved salvage treatment approaches...
  3. doi request reprint ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
    M Dreyling
    Department of Medicine III, University Hospital, LMU Munich, Germany
    Ann Oncol 24:857-77. 2013
    ..A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia...
  4. doi request reprint Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network
    Martin Dreyling
    Department of Medicine III, University Hospital Großhadern LMU Munich, Germany
    Leuk Lymphoma 54:699-707. 2013
    ..At the annual conference in Lisbon, recent results of molecular pathogenesis, analyses of current clinical trials and new study concepts were discussed...
  5. doi request reprint Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network
    Martin Dreyling
    Department of Medicine III, University Hospital Grosshadern LMU Munich, Munich, Germany
    Leuk Lymphoma 52:2226-36. 2011
    ..At the annual conference in Warsaw, recent results of molecular pathogenesis, analyses of current clinical trials and new study concepts were discussed...
  6. ncbi request reprint Hyper-CVAD in mantle-cell lymphoma: really "hyper" or just hype?
    Martin Dreyling
    Department of Medicine III, University of Munich Campus, Grosshadern, Germany
    Leuk Lymphoma 49:1017-8. 2008
  7. ncbi request reprint [Up-to-date treatment of follicular lymphomas]
    M Dreyling
    Medizinische Klinik III, Klinikum der Ludwig Maximilians Universität München, Grosshadern
    Dtsch Med Wochenschr 130:2149-54. 2005
  8. doi request reprint Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
    Martin Dreyling
    University Hospital Grosshadern, Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
    Curr Opin Oncol 20:487-94. 2008
    ..Conventional-dosed chemotherapy achieves only temporary responses with a median duration of remissions of only 1-2 years...
  9. ncbi request reprint Combination of biologicals in indolent lymphoma: finally the end of chemotherapy era in indolent lymphoma?
    Martin Dreyling
    Medizinische Klinik III der Universität Münich Grosshadern, Germany
    Leuk Lymphoma 49:8-9. 2008
  10. ncbi request reprint [Therapy of mantle cell lymphoma]
    M Dreyling
    Med Klinik und Poliklinik III, Klinikum der Universitat Munchen Grosshadern, Marchioninistrasse 15, 81377, Munchen, Deutschland
    Internist (Berl) 48:382-8. 2007
    ..However, numerous molecular targeting strategies (e.g. proteasome inhibitors, immunomodulatory drugs or radiolabeled antibodies) have achieved promising results in early phase II studies...
  11. ncbi request reprint Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference
    Martin Dreyling
    Department of Medicine III, University Hospital Grosshadern LMU Munich, Munich, Germany
    Leuk Lymphoma 51:1612-22. 2010
    ..At the recent annual conference in Jerusalem, recent results of molecular pathogenesis, analyses of current clinical trials, and new study concepts were discussed...
  12. ncbi request reprint Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy
    M Dreyling
    Department of Medicine III, Grosshadern, Ludwig Maximilians University, Munich, Germany
    Ann Hematol 86:81-7. 2007
    ..Current study concepts evaluate the role of RIT consolidation in combination with antibody maintenance to achieve a potentially curative approach even in patients with advanced stage disease...
  13. ncbi request reprint [Current strategies in the treatment of advanced stage mantle cell lymphoma]
    G Lenz
    Medizinische Klinik III, Klinikum der Ludwig Maximilians Universität, Munchen
    Dtsch Med Wochenschr 129:2429-33. 2004
    ..g. proteasome inhibitors or radiolabeled antibodies) are urgently warranted to further improve the long-term outcome of MCL...
  14. ncbi request reprint Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
    O Weigert
    Department of Internal Medicine III, University of Munich, University Hospital Grosshadern, Munich, Germany
    Leukemia 21:524-8. 2007
    ..Interestingly, efficacy in vitro correlated with sequence of treatment, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach...
  15. ncbi request reprint Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group
    C Nickenig
    Department of Internal Medicine III, Ludwig Maximilians University, Munich Grosshadern, Germany
    Ann Oncol 18:136-42. 2007
    ....
  16. doi request reprint The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Gro
    C Buske
    Department of Internal Medicine III, University of Munich, Munich, Germany
    Leukemia 23:153-61. 2009
    ..0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM...
  17. doi request reprint Current treatment standards and future strategies in mantle cell lymphoma
    M Dreyling
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Ann Oncol 19:iv41-4. 2008
  18. ncbi request reprint Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly
    Christina Nickenig
    Department of Internal Medicine III, Ludwig Maximilians University, Munich Grosshadern, Germany
    Cancer 107:1014-22. 2006
    ..In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades...
  19. ncbi request reprint Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
    Roswitha Forstpointner
    Department of Internal Medicine III, University of Munich, Grosshadern Marchioninistr 15, 81377 Munchen, Germany
    Blood 108:4003-8. 2006
    ..035) and MCL (P = .049) separately. Hence, R-maintenance is effective after salvage with R-chemotherapy and significantly prolongs response duration in patients with recurring or refractory FL or MCL...
  20. ncbi request reprint Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma
    M Dreyling
    Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
    Ann Oncol 16:ii99-104. 2005
  21. ncbi request reprint Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
    Georg Lenz
    Department of Internal Medicine III, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Blood 104:2667-74. 2004
    ..Longer follow-up is necessary to determine the effect of ASCT on overall survival...
  22. ncbi request reprint The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
    Roswitha Forstpointner
    Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, Marchioninistr 15 81377 München, Germany
    Blood 104:3064-71. 2004
    ..0042). There were no differences in clinically relevant side effects in both study arms. Hence, the addition of rituximab to FCM chemotherapy significantly improves the outcome of relapsed or refractory FL and MCL...
  23. ncbi request reprint Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results o
    Georg Lenz
    Department of Internal Medicine III of the Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    J Clin Oncol 23:1984-92. 2005
    ....
  24. ncbi request reprint Investigational strategies in autologous stem cell transplantation for follicular lymphoma
    Oliver Weigert
    Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
    Curr Oncol Rep 8:368-75. 2006
    ..Combination of these novel strategies into a multimodal approach justifies hope that the treatment outcome of patients suffering from follicular lymphoma will be further improved...
  25. doi request reprint [Current clinical aspects of follicular lymphoma]
    Martin Dreyling
    Medizinische Klinik III, Klinikum der Universität München Campus Großhadern, Munchen
    Ther Umsch 67:511-6. 2010
    ..Accordingly, current series report on an improved median overall survival of 15-20 years...
  26. ncbi request reprint Mantle cell lymphoma: established therapeutic options and future directions
    G Lenz
    Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, 81377 Munich, Germany
    Ann Hematol 83:71-7. 2004
    ..Thus, new therapeutic strategies such as radioactively labeled antibodies or molecular targeting agents (e.g. Bortezomib or flavopiridol) are urgently warranted to further improve the clinical outcome of mantle cell lymphoma...
  27. ncbi request reprint Therapy of mantle cell lymphoma: current standards and future strategies
    Christian Schmidt
    Department of Medicine III, University of Munich, Hospital Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Hematol Oncol Clin North Am 22:953-63, ix. 2008
    ..New concepts of therapy are urgently warranted, including new molecular approaches, such as bortezomib, thalidomide, lenalidomide, and temsirolimus...
  28. ncbi request reprint [Prophylaxis and differential therapy of tumorlysis syndrome]
    M Krych
    Medizinische Klinik und Poliklinik III Grosshadern, Ludwig Maximilians Universitat Munchen, Munich
    Dtsch Med Wochenschr 129:1440-5. 2004
  29. doi request reprint A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
    Oliver Weigert
    Department of Internal Medicine III, University of Munich, Munich, Germany
    Leuk Lymphoma 50:716-22. 2009
    ..Median progression free and overall survival were 5 and 15.5 months, respectively. The combination of bortezomib and a high-dose cytarabine-containing regimen has activity in heavily pretreated patients with relapsed or refractory MCL...
  30. ncbi request reprint Current management of mantle cell lymphoma
    Oliver Weigert
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Drugs 67:1689-702. 2007
    ..This article addresses these issues providing relevant information for current state-of-the-art management of patients with mantle cell lymphoma and giving a perspective of upcoming treatment strategies...
  31. doi request reprint 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma
    Marc Weinkauf
    CCG Leukemia, Department of Medicine III, University Hospital Grosshadern LMU, Munich, Germany, in association with Helmholtz Center Munich, Munich, Germany
    Electrophoresis 30:974-86. 2009
    ..The results were confirmed in primary mantle cell lymphoma, thus confirming the critical role of these candidate proteins of proteasome inhibition...
  32. ncbi request reprint Current management of follicular lymphomas
    Wolfgang Hiddemann
    Department of Internal Medicine III, University of Munich, Munich, Germany
    Br J Haematol 136:191-202. 2007
    ..New therapeutic perspectives have also emerged from increasing insights into the biology of the disease that unravel molecular targets for novel agents, some of which have entered clinical evaluation already...
  33. ncbi request reprint Treatment strategies in follicular lymphomas: current status and future perspectives
    Wolfgang Hiddemann
    Department of Internal Medicine III, University of Munich, Marchioninistr 15, 81377 Munich, Germany
    J Clin Oncol 23:6394-9. 2005
    ..New therapeutic perspectives also emerge from increasing insights into the biology of the disease that unravel molecular targets for novel agents, some of which have entered clinical evaluation already...
  34. ncbi request reprint Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: r
    Wolfgang Hiddemann
    Department of Internal Medicine III, University of Munich, Grosshadern Marchioninistr 15, 81377 Munchen, Germany
    Blood 106:3725-32. 2005
    ..Hence, adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects...
  35. ncbi request reprint Transplantation strategies for patients with follicular lymphoma
    Christian Buske
    Department of Internal Medicine III, University of Munich, GroBhadern, Germany
    Curr Opin Hematol 12:266-72. 2005
    ....
  36. ncbi request reprint [Monoclonal antibody therapy for malignant lymphoma]
    Christian Buske
    Medizinische Klinik III, Klinikum der Universitat Munchen, Grosshadern, Marchioninistrasse 15, 81377 Munchen
    Med Klin (Munich) 100:14-24. 2005
    ....
  37. ncbi request reprint Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
    Georg Lenz
    Lymphoma Section, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
    Nat Clin Pract Oncol 2:72-3. 2005
  38. ncbi request reprint Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Gro
    Georg Lenz
    Department of Internal Medicine III, Ludwig Maximilians University, University Hospital Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
    J Clin Oncol 22:4926-33. 2004
    ....
  39. ncbi request reprint The role of fludarabine in the treatment of follicular and mantle cell lymphoma
    Georg Lenz
    Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
    Cancer 101:883-93. 2004
    ..Consequently, current research efforts have focused on the use of fludarabine-containing combinations in the first-line treatment of FL and MCL...
  40. ncbi request reprint Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia
    Georg Lenz
    Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
    Ann Hematol 83:628-33. 2004
    ..The reduced mRNA expression in additional samples may indicate an involvement of hMLH1 in the malignant transformation in a small subset of cases. In contrast, MGMT does not seem to be involved in the pathogenesis of AML...
  41. ncbi request reprint Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement
    Mirjam Klaus
    Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, 81377 Munich, Germany
    Cancer Genet Cytogenet 144:36-43. 2003
    ..Compared to translocations involving MLL and other partner genes, complex rearrangements are unique for MLL-AF10 fusions. This may result from the opposite orientation of MLL and AF10...
  42. ncbi request reprint Current status and perspective of antibody therapy in follicular lymphoma
    Christian Buske
    Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
    Haematologica 91:104-12. 2006
    ....
  43. ncbi request reprint The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vinc
    Christian Buske
    Department of Internal Medicine III, University of Munich, Grosshadern, Marchioninistr 15, 81377 Munchen, Germany
    Blood 108:1504-8. 2006
    ..001). Our data demonstrate that the FLIPI is able to identify high-risk patients with advanced-stage FL after first-line treatment with rituximab/chemotherapy...
  44. doi request reprint Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells
    Valeria Milani
    Department of Medical Oncology, University Medical Center Grosshadern, 81377 Munich, Germany
    Int J Hyperthermia 25:262-72. 2009
    ..In conclusion, these results suggest that the application of bortezomib, under thermal conditions, in mantle cell lymphoma cells may be beneficial and warrants further investigation...
  45. doi request reprint Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
    M Dreyling
    Department of Medicine III, University Hospital Grosshadern, Munich, Germany
    Ann Oncol 19:ii77-8. 2008
  46. ncbi request reprint A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
    Eva Hoster
    Department of Internal Medicine III, University of Munich, Germany
    Blood 111:558-65. 2008
    ..The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL...
  47. doi request reprint Mantle cell lymphoma: state-of-the-art management and future perspective
    Oliver Weigert
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Leuk Lymphoma 50:1937-50. 2009
    ..This article will provide relevant information for decision making in clinical practice and give a perspective on upcoming management strategies...
  48. ncbi request reprint Mantle cell lymphoma: therapeutic strategies are different from CLL
    Wolfgang Hiddemann
    Department of Medicine III, University Hospital Grosshadern LMU, Marchioninistrasse 15, 81377 Munich, Germany
    Curr Treat Options Oncol 4:219-26. 2003
    ..Prospective randomized trials remain critical to further improve the clinical course of MCL with the addition of newer treatment modalities, such as radioactively labeled antibodies and targeted therapies (eg, flavopiridol and PS-341)...
  49. ncbi request reprint Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background
    Marc Weinkauf
    Department of Medicine III, University Hospital Grosshadern LMU, Munich, Germany
    Electrophoresis 27:4555-8. 2006
    ....
  50. ncbi request reprint 3'UTR mediated regulation of the cyclin D1 proto-oncogene
    Anagha Deshpande
    Department of Medicine III, Klinikum Grosshadern, Munich, Germany
    Cell Cycle 8:3584-92. 2009
    ....
  51. ncbi request reprint Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma
    Marc Weinkauf
    CCG Leukemia, Department of Medicine III, University Hospital Grosshadern LMU, Munich, Germany
    Electrophoresis 28:4416-26. 2007
    ..36). Most interestingly, additional data bank search identified 13 out of 17 referenced proteins (76%) as members of a TP53-dependent network of cell regulation...
  52. ncbi request reprint Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma
    Oliver Weigert
    Department of Internal Medicine III, University of Munich, Munich, Germany
    Cancer 107:686-95. 2006
    ....
  53. doi request reprint Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation
    G Hutter
    Department of Medicine III, University Hospital Grosshadern LMU, CCG Leukemia, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany
    Ann Hematol 88:821-8. 2009
    ..This proliferation-dependent network of oncogenic alterations complements the previously identified proliferation expression signature described by RNA expression profiling in MCL...
  54. ncbi request reprint Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell
    Tiemo Katzenberger
    Institute of Pathology, University of Wurzburg, Department of Medicine III, University Hospital Grosshadern LMU München, Germany
    Blood 101:699-702. 2003
    ..On the basis of these findings, CD5(+) DLBLs are likely to arise from the same progenitor cell as the mutated variant of CD5(+) lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (B-CLL)...
  55. ncbi request reprint Use of polymorphisms in the noncoding region of the human mitochondrial genome to identify potential contamination of human leukemia-lymphoma cell lines
    Grit Hutter
    Department of Medicine III, University Hospital Grosshadern LMU, GSF Clinical Cooperative Group Leukemia, Germany
    Hematol J 5:61-8. 2004
    ..In comparison to other methods (cytogenetics, fluorescence in situ hybridization or immunophenotyping), this technique is less laborious and time consuming...
  56. doi request reprint Improvement of overall survival in advanced stage mantle cell lymphoma
    Annina Herrmann
    Department of Internal Medicine III, University of Munich, Germany
    J Clin Oncol 27:511-8. 2009
    ..To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004)...
  57. ncbi request reprint Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma
    Grit Hutter
    Department of Medicine III, University Hospital Grosshadern LMU, CCG Leukemia, GSF National Research Center for Environment and Health, Munich, Germany
    Genes Chromosomes Cancer 45:203-10. 2006
    ..The rare p16(INK4a) promoter methylation and p16(INK4a) genetic alterations were directly correlated to cell proliferation and therefore are regarded as additional molecular alterations involved in the cell-cycle dysregulation of MCL...
  58. ncbi request reprint Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease
    Bärbel Seyfarth
    Department of Internal Medicine I, Westpfalz Klinikum, Kaiserslautern, Germany
    Br J Haematol 133:3-18. 2006
    ..We focus on follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin disease since these are most frequent and evidence-based salvage strategies are beginning to emerge...
  59. ncbi request reprint Rituximab plus chemotherapy in follicular and mantle cell lymphomas
    Wolfgang Hiddemann
    University of Munich, Germany
    Semin Oncol 30:16-20. 2003
    ..A trend towards longer overall and disease-free survival for rituximab plus FCM has been observed, but longer follow-up is required...
  60. ncbi request reprint Indolent lymphomas: current and emerging treatment approaches
    David Maloney
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ....
  61. ncbi request reprint Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  62. ncbi request reprint Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
    Christiane Pott
    Second Medical Department, University Hospital Schleswig Holstein, Campus Kiel, Chemnitzstr 33, 24116 Kiel, Germany
    Blood 107:2271-8. 2006
    ..We conclude that sequential quantitative monitoring of residual disease after ASCT is a powerful indicator for treatment outcome in MCL and defines subgroups of patients with a significantly different prognosis...
  63. doi request reprint Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
    Sebastian Böttcher
    Second Department of Medicine, Chemnitzstrasse 33, D 24116 Kiel, Germany
    Haematologica 93:551-9. 2008
    ..Data from prospective clinical trials comparing the clinical applicability of flow cytometry to routine diagnostic methods and to polymerase chain reaction are currently lacking...
  64. ncbi request reprint Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    Holger Schulz
    Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:706-14. 2007
    ....
  65. ncbi request reprint High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
    Rudolf Weide
    Praxisklinik for Hematology and Oncology, Koblenz, Germany
    Leuk Lymphoma 48:1299-306. 2007
    ..BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory FL, MCL and other indolent lymphomas...
  66. ncbi request reprint Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group
    Wolfram Klapper
    Department of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany
    J Clin Oncol 25:3330-6. 2007
    ..Several histopathologic biomarkers for risk stratification have been suggested, but most markers have not been validated in patients treated in prospective trials...
  67. ncbi request reprint Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events
    Gerhard Herzog
    Haematologica 90:693-5. 2005
    ..We performed allelotyping and p53 mutation analysis in 75 patients with morphologically and cytogenetically classified AML...
  68. ncbi request reprint Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group
    Olaf Determann
    Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Blood 111:2385-7. 2008
    ..013). Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy. The Euro-pean MCL study is registered at www.ClinicalTrials.gov as #NCT00016887...
  69. doi request reprint Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
    Ralf U Trappe
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transplantation 84:1708-12. 2007
    ..Single-agent rituximab salvage therapy is an effective treatment option in this setting of intensively pretreated patients, with virtually no therapy-associated toxicity...
  70. doi request reprint Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma
    Inga Nieländer
    Haematologica 93:949-50. 2008
  71. ncbi request reprint Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue
    Elena Hartmann
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    J Clin Oncol 26:4966-72. 2008
    ....